SURMOUNT trials
Tirzepatide obesity trial program. SURMOUNT-1 showed ~21% mean weight loss.
The SURMOUNT program established tirzepatide (Zepbound) for obesity. SURMOUNT-1 showed about 21% mean body-weight reduction at 72 weeks on the 15mg dose; SURMOUNT-5 was a head-to-head win over semaglutide.